Access cutting-edge al amyloidosis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access al amyloidosis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related al amyloidosis treatment provided free
Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383. Etentamig (ABBV-383) is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into
Sponsor: AbbVie
Check if you qualify for this al amyloidosis clinical trial in New York, NY
If you're searching for al amyloidosis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced al amyloidosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.